BECOME A MEMBER
Connect with healthcare professionals around the globe to get the most up-to-date medical cannabis information.
Get Involved
TAKE OUR COURSES
The curriculum brings hands-on practical guidance on how to develop personalized treatment regimens and more.
Genetic variations in the human cannabinoid receptor gene are associated with happiness.
Authors: Masahiro Matsunaga , Tokiko Isowa, Kaori Yamakawa, Seisuke Fukuyama, Jun Shinoda, et al
PLoS One, 1 April 2014
—
Happiness has been viewed as a temporary emotional state (e.g., pleasure) and a relatively stable state of being happy (subjective happiness level). As previous studies demonstrated that individuals with high subjective happiness level rated their current affective states more…
Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study.
Authors: Itay Lotan, Therese Treves, Yaniv Roditi, Ruth Djaldetti
Clinical Neuropharmacology, March-April 2014
—
OBJECTIVE: The use of cannabis as a therapeutic agent for various medical conditions has been well documented. However, clinical trials in patients with Parkinson disease (PD) have yielded conflicting results. The aim of the present open-label observational study was to assess…
Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system.
Authors: John M. McPartland, Geoffrey W. Guy, Vincenzo Di Marzo
PLoS One, 12 March 2014
—
BACKGROUND: The “classic” endocannabinoid (eCB) system includes the cannabinoid receptors CB1 and CB2, the eCB ligands anandamide (AEA) and 2-arachidonoylglycerol (2-AG), and their metabolic enzymes. An emerging literature documents the “eCB deficiency syndrome” as an etiology…
Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic.
Authors: Ester Aso, Isidre Ferrer
Frontiers in Pharmacology, 5 March 2014
—
The limited effectiveness of current therapies against Alzheimer’s disease (AD) highlights the need for intensifying research efforts devoted to developing new agents for preventing or retarding the disease process. During the last few years, targeting the endogenous cannabino…
Cannabinoids for epilepsy.
Authors: David Gloss, Barbara Vickrey
Cochrane Database of Systematic Reviews, 5 March 2014
—
BACKGROUND: Marijuana appears to have anti-epileptic effects in animals. It is not currently known if it is effective in patients with epilepsy. Some states in the United States of America have explicitly approved its use for epilepsy. OBJECTIVES: To assess the efficacy and sa…
PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program.
Authors: George R. Greer, Charles S. Grob, Adam L. Halberstadt
Journal of Psychoactive Drugs, January-March 2014
—
BACKGROUND: New Mexico was the first state to list post-traumatic stress disorder (PTSD) as a condition for the use of medical cannabis. There are no published studies, other than case reports, of the effects of cannabis on PTSD symptoms. The purpose of the study was to report…
Targeting endocannabinoid signaling in tumor‐associated macrophages as treatment for glioblastoma multiforme
Authors: Susan Fung, Nephi Stella
Wiley Interdisciplinary Reviews: Membrane Transport and Signaling, 21 January 2014
—
Glioblastoma multiforme (GBM) is the most common form of primary brain tumor and is diagnosed in approximately 15,000 people each year in the United States alone. No cure for this type of cancer exists, and the current standard of care treatments provide little benefit and are…
A controlled family study of cannabis users with and without psychosis.
Authors: Ashley C. Proal, Jerry Fleming, Juan A. Galvez-Buccollini, Lynn E. DeLisi
Schizophrenia Research, January 2014
—
BACKGROUND: Cannabis is one of the most highly abused illicit drugs in the world. Several studies suggest a link between adolescent cannabis use and schizophrenia. An understanding of this link would have significant implications for legalization of cannabis and its medicinal…
Association between pre- and perinatal exposures and Tourette syndrome or chronic tic disorder in the ALSPAC cohort.
Authors: Carol A. Mathews, Jeremiah M. Scharf, Laura L. Miller, Corrie Macdonald-Wallis, et al
British Journal of Psychiatry, January 2014
—
BACKGROUND: Tourette syndrome and chronic tic disorder are heritable but aetiologically complex. Although environment plays a role in their development, existing studies of non-genetic risk factors are inconsistent. AIMS:
To examine the association between pre- and perinatal e…
Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence.
Authors: Wilfrid Noel Raby, Kenneth M. Carpenter, Jami Rothenberg, Adam C. Brooks, Huiping Jiang, et al
American Journal on Addictions, July/August 2009
—
Naltrexone is a theoretically promising alternative to agonist substitution treatment for opioid dependence, but its effectiveness has been severely limited by poor adherence. This study examined, in an independent sample, a previously observed association between moderate can…
Alterations of endocannabinoids in cerebrospinal fluid of dogs with epileptic seizure disorder.
Authors: Felix K Gesell, Alexander A Zoerner, Christina Brauer, Stefan Engeli, Dimitros Tsikas, Andrea Tipold
BMC Veterinary Research, 26 December 2013
—
BACKGROUND: Epilepsy is one of the most common chronic neurological disorders in dogs characterized by recurrent seizures. The endocannabinoid (EC) system plays a central role in suppressing pathologic neuronal excitability and in controlling the spread of activity in an epile…
Cannabis finds its way into treatment of Crohn’s disease.
Authors: Rudolf Schicho, Martin Storr
Pharmacology, 2014
—
In ancient medicine, cannabis has been widely used to cure disturbances and inflammation of the bowel. A recent clinical study now shows that the medicinal plant Cannabis sativa has lived up to expectations and proved to be highly efficient in cases of inflammatory bowel disea…